Upstream Bio, Inc. Files Q1 2025 10-Q
Ticker: UPB · Form: 10-Q · Filed: May 6, 2025 · CIK: 2022626
| Field | Detail |
|---|---|
| Company | Upstream Bio, Inc. (UPB) |
| Form Type | 10-Q |
| Filed Date | May 6, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, IPO, biotech, financials
TL;DR
Upstream Bio Q1 2025 10-Q filed. IPO in Oct '24, Lonza deal active. Financials updated.
AI Summary
Upstream Bio, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial position and business activities, including details related to its IPO in October 2024 and the Lonza License Agreement. Key financial data points such as Additional Paid-In Capital and Retained Earnings were updated as of March 31, 2025.
Why It Matters
This filing provides investors with an update on Upstream Bio's financial health and operational progress following its recent IPO, offering insights into its capital structure and ongoing agreements.
Risk Assessment
Risk Level: medium — As a biotech company that recently had an IPO, Upstream Bio faces inherent risks related to drug development, market adoption, and financial performance.
Key Numbers
- 2025-03-31 — Reporting Date (The period covered by this 10-Q filing.)
- 2024-10-01 2024-10-31 — IPO Period (The timeframe during which the company's Initial Public Offering occurred.)
Key Players & Entities
- Upstream Bio, Inc. (company) — Filer of the 10-Q
- March 31, 2025 (date) — Period end date for the 10-Q
- October 2024 (date) — Date of the company's IPO
- Lonza License Agreement (agreement) — Key agreement mentioned in the filing
FAQ
What was the total Additional Paid-In Capital as of March 31, 2025?
The filing indicates that Additional Paid-In Capital was reported as of March 31, 2025, but the specific dollar amount is not detailed in the provided header information.
What is the status of the Lonza License Agreement during the first quarter of 2025?
The filing references the Lonza License Agreement for the period of January 1, 2025, to March 31, 2025, suggesting it was active during this time.
When did Upstream Bio, Inc. have its Initial Public Offering (IPO)?
Upstream Bio, Inc.'s IPO occurred in October 2024.
What is the company's fiscal year end?
Upstream Bio, Inc.'s fiscal year ends on December 31.
What is the business address of Upstream Bio, Inc.?
The business address is 890 WINTER STREET, SUITE 200, WALTHAM, MA 02451.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 6, 2025 regarding Upstream Bio, Inc. (UPB).